Margaret Kweku
University of London
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Margaret Kweku.
PLOS Medicine | 2009
Richard Pearce; Hirva Pota; Marie-Solange Evehe; El-Hadj Bâ; Ghyslain Mombo-Ngoma; Allen L Malisa; Rosalynn Ord; Walter Inojosa; Alexandre Matondo; Diadier Diallo; Wilfred F. Mbacham; Ingrid van den Broek; Todd Swarthout; Asefaw Getachew; Seyoum Dejene; Martin P. Grobusch; Fanta Njie; Samuel K. Dunyo; Margaret Kweku; Seth Owusu-Agyei; Daniel Chandramohan; Maryline Bonnet; Jean-Paul Guthmann; Sîan E. Clarke; Karen I. Barnes; Elizabeth Streat; Stark Katokele; Petrina Uusiku; Chris O. Agboghoroma; Olufunmilayo Y. Elegba
Cally Roper and colleagues analyze the distribution of sulfadoxine resistance mutations and flanking microsatellite loci to trace the emergence and dispersal of drug-resistant Plasmodium falciparum malaria in Africa.
PLOS ONE | 2008
Margaret Kweku; Dongmei Liu; Martin Adjuik; Fred Binka; Mahmood Seidu; Brian Greenwood; Daniel Chandramohan
Background Malaria and anaemia are the leading causes of morbidity and mortality in children in sub-Saharan Africa. We have investigated the effect of intermittent preventive treatment with sulphadoxine-pyrimethamine or artesunate plus amodiaquine on anaemia and malaria in children in an area of intense, prolonged, seasonal malaria transmission in Ghana. Methods 2451 children aged 3–59 months from 30 villages were individually randomised to receive placebo or artesunate plus amodiaquine (AS+AQ) monthly or bimonthly, or sulphadoxine-pyrimethamine (SP) bimonthly over a period of six months. The primary outcome measures were episodes of anaemia (Hb<8.0 g/dl) or malaria detected through passive surveillance. Findings Monthly artesunate plus amodiaquine reduced the incidence of malaria by 69% (95% CI: 63%, 74%) and anaemia by 45% (95% CI: 25%,60%), bimonthly sulphadoxine-pyrimethamine reduced the incidence of malaria by 24% (95% CI: 14%,33%) and anaemia by 30% (95% CI: 6%, 49%) and bimonthly artesunate plus amodiaquine reduced the incidence of malaria by 17% (95% CI: 6%, 27%) and anaemia by 32% (95% CI: 7%, 50%) compared to placebo. There were no statistically significant reductions in the episodes of all cause or malaria specific hospital admissions in any of the intervention groups compared to the placebo group. There was no significant increase in the incidence of clinical malaria in the post intervention period in children who were >1 year old when they received IPTc compared to the placebo group. However the incidence of malaria in the post intervention period was higher in children who were <1 year old when they received AS+AQ monthly compared to the placebo group. Interpretation IPTc is safe and efficacious in reducing the burden of malaria in an area of Ghana with a prolonged, intense malaria transmission season. Trial Registration ClinicalTrials.gov NCT00119132
Malaria Journal | 2009
Anne Liljander; Lisa Wiklund; Nicole Falk; Margaret Kweku; Andreas Mårtensson; Ingrid Felger; Anna Färnert
BackgroundGenotyping of Plasmodium falciparum based on PCR amplification of the polymorphic genes encoding the merozoite surface proteins 1 and 2 (msp1 and msp2) is well established in the field of malaria research to determine the number and types of concurrent clones in an infection. Genotyping is regarded essential in anti-malarial drug trials to define treatment outcome, by distinguishing recrudescent parasites from new infections. Because of the limitations in specificity and resolution of gel electrophoresis used for fragment analysis in most genotyping assays it became necessary to improve the methodology. An alternative technique for fragment analysis is capillary electrophoresis (CE) performed using automated DNA sequencers. Here, one of the most widely-used protocols for genotyping of P. falciparum msp1 and msp2 has been adapted to the CE technique. The protocol and optimization process as well as the potentials and limitations of the technique in molecular epidemiology studies and anti-malarial drug trials are reported.MethodsThe original genotyping assay was adapted by fluorescent labeling of the msp1 and msp2 allelic type specific primers in the nested PCR and analysis of the final PCR products in a DNA sequencer. A substantial optimization of the fluorescent assay was performed. The CE method was validated using known mixtures of laboratory lines and field samples from Ghana and Tanzania, and compared to the original PCR assay with gel electrophoresis.ResultsThe CE-based method showed high precision and reproducibility in determining fragment size (< 1 bp). More genotypes were detected in mixtures of laboratory lines and blood samples from malaria infected children, compared to gel electrophoresis. The capacity to distinguish recrudescent parasites from new infections in an anti-malarial drug trial was similar by both methods, resulting in the same outcome classification, however with more precise determination by CE.ConclusionThe improved resolution and reproducibility of CE in fragment sizing allows for comparison of alleles between separate runs and determination of allele frequencies in a population. The more detailed characterization of individual msp1 and msp2 genotypes may contribute to improved assessments in anti-malarial drug trials and to a further understanding of the molecular epidemiology of these polymorphic P. falciparum antigens.
PLOS ONE | 2009
Margaret Kweku; Jayne Webster; Martin Adjuik; Samuel Abudey; Brian Greenwood; Daniel Chandramohan
Background Intermittent preventive treatment for malaria in children (IPTc) is a promising new intervention for the prevention of malaria but its delivery is a challenge. We have evaluated the coverage of IPTc that can be achieved by two different delivery systems in Ghana. Methods IPTc was delivered by volunteers in six villages (community-based arm) and by health workers at health centres or at Expanded Programme on Immunisation outreach clinics (facility based) in another six communities. The villages were selected randomly and drugs were administered in May, June, September and October 2006. The first dose of a three-dose regimen of amodiaquine plus sulphadoxine-pyrimethamine was administered under supervision to 3–59 month-old children (n = 964) in the 12 study villages; doses for days 2 and 3 were given to parents/guardians to administer at home. Results The proportion of children who received at least the first dose of 3 or more courses of IPTc was slightly higher in the community based arm (90.5% vs 86.6%; p = 0.059). Completion of the three dose regimen was high and similar with both delivery systems (91.6% and 91.7% respectively). Conclusion Seasonal IPTc delivered through community-based or facility-based systems can achieve a high coverage rate with the support and supervision of the district health management team. However, in order to maximise the impact of IPTc, both delivery systems may be needed in some settings. Trial Registration ClinicalTrials.gov NCT00119132
PLOS ONE | 2010
Lesong Conteh; Edith Patouillard; Margaret Kweku; Rosa Legood; Brian Greenwood; Daniel Chandramohan
Background Intermittent preventive treatment for malaria in children (IPTc) involves the administration of a full course of an anti-malarial treatment to children under 5 years old at specified time points regardless of whether or not they are known to be infected, in areas where malaria transmission is seasonal. It is important to determine the costs associated with IPTc delivery via community based volunteers and also the potential savings to health care providers and caretakers due to malaria episodes averted as a consequence of IPTc. Methods Two thousand four hundred and fifty-one children aged 3–59 months were randomly allocated to four groups to receive: three days of artesunate plus amodiaquine (AS+AQ) monthly, three days of AS+AQ bimonthly, one dose of sulphadoxine-pyrimethamine (SP) bi-monthly or placebo. This paper focuses on incremental cost effectiveness ratios (ICERs) of the three IPTc drug regimens as delivered by community based volunteers (CBV) in Hohoe, Ghana compared to current practice, i.e. case management in the absence of IPTc. Financial and economic costs from the publicly funded health system perspective are presented. Treatment costs borne by patients and their caretakers are also estimated to present societal costs. The costs and effects of IPTc during the intervention period were considered with and without a one year follow up. Probabilistic sensitivity analysis was undertaken to account for uncertainty. Results Economic costs per child receiving at least the first dose of each course of IPTc show SP bimonthly, at US
Malaria Journal | 2007
Margaret Kweku; Jayne Webster; Ian Taylor; Susan Burns; McDamien Dedzo
8.19, is the cheapest to deliver, followed by AS+AQ bimonthly at US
American Journal of Tropical Medicine and Hygiene | 2010
Jayne Webster; Margaret Kweku; McDamien Dedzo; Kojo Tinkorang; Jane Bruce; Jo Lines; Daniel Chandramohan; Kara Hanson
10.67 and then by AS+AQ monthly at US
Malaria Journal | 2013
Neils B. Quashie; Nancy O. Duah; Benjamin K. Abuaku; Lydia Quaye; Ruth Ayanful-Torgby; George A Akwoviah; Margaret Kweku; Jacob D. Johnson; Naomi W. Lucchi; Venkatachalam Udhayakumar; Christopher Duplessis; Karl C. Kronmann; Kwadwo A. Koram
14.79. Training, drug delivery and supervision accounted for approximately 20–30% each of total unit costs. During the intervention period AS & AQ monthly was the most cost effective IPTc drug regimen at US
PLOS ONE | 2010
Anne Liljander; Daniel Chandramohan; Margaret Kweku; Daniel Olsson; Scott M. Montgomery; Brian Greenwood; Anna Färnert
67.77 (61.71–74.75, CI 95%) per malaria case averted based on intervention costs only, US
The Pan African medical journal | 2017
Kunche Delali Nyavor; Margaret Kweku; Isaac Agbemafle; Wisdom Takramah; Ishmael D. Norman; Elvis Tarkang; Fred Binka
64.93 (58.92–71.92, CI 95%) per malaria case averted once the provider cost savings are included and US